Torren Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Torren Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8	Closed	-$475	–	1055
2025 Q4	$475	Buy	+8	New	+$436	﹤0.01%	1345

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Torren Management's BMRN Position: Q1 2026 in Review

Torren Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 8 shares — an estimated $475 sold.

Torren Management first reported a position in BMRN in Q4 2025 and held it in 1 quarter. The position peaked at $475 in Q4 2025. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Torren Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Torren Management sold 8 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $475.
Torren Management first reported a position in BioMarin Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Torren Management's BioMarin Pharmaceuticals position peaked at $475 in Q4 2025.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.